News from our Corporate Partner Takeda

Takeda issued a statement on 4 October 2022 that it will discontinue the global manufacturing NATPAR^® (parathyroid hormone) for injection at the end of 2024, due to unresolved supply issues specific to the product.

Until the end of 2024, Takeda’s key priority is to maintain treatment continuity for patients who are currently receiving NATPAR, subject to available supply. This includes all patients receiving NATPAR in Europe and other regions around the world. Beyond 2024, Takeda intends to supply available doses until inventory is depleted or expired. Takeda will provide updates before the manufacturing end date and ahead of any potential supply interruptions.

The full statement can be found HERE.